The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
An organic molecule that is electrically neutral carrying a positive and a negative charge in one of its major canonical descriptions. In most dipolar compounds the charges are delocalized; however the term is also applied to species where this is not the case.
Carnitine results in decreased expression of BAX protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in decreased expression of BAX protein]; Carnitine inhibits the reaction [Atrazine results in increased expression of BAX mRNA]; Carnitine inhibits the reaction [Methotrexate results in increased expression of BAX protein]
Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]; Ketoglutaric Acids inhibits the reaction [Aluminum inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]; Ketoglutaric Acids inhibits the reaction [Hydrogen Peroxide inhibits the reaction [BBOX1 protein results in increased chemical synthesis of Carnitine]]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Carnitine results in increased phosphorylation of BCL2 protein]; Carnitine inhibits the reaction [Atrazine results in decreased expression of BCL2 mRNA]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of BCL2 mRNA]; Carnitine inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein]
Carnitine inhibits the reaction [Atrazine results in increased expression of CASP3 mRNA]; Carnitine inhibits the reaction [Gentamicins results in increased cleavage of CASP3 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP3 mRNA]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of CASP3 mRNA]]; Carnitine inhibits the reaction [Methotrexate results in increased expression of CASP3 protein] Carnitine inhibits the reaction [quinone results in increased activity of CASP3 protein]
Carnitine inhibits the reaction [Ifosfamide results in increased expression of CASP9 mRNA] Carnitine inhibits the reaction [quinone results in increased activity of CASP9 protein]
Carnitine inhibits the reaction [Diethylnitrosamine results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; Carnitine inhibits the reaction [Ifosfamide results in decreased expression of CAT mRNA]
Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of COL1A1 mRNA]; Carnitine inhibits the reaction [Sunitinib results in increased expression of COL1A1 mRNA]
[COL2A1 protein co-treated with Freund's Adjuvant] affects the abundance of Carnitine; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; huang-lien-chieh-tu-tang inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]
valproyl-coenzyme A inhibits the reaction [CPT1A protein results in increased metabolism of Carnitine] [Doxorubicin co-treated with Carnitine] results in increased expression of CPT1A mRNA; [Genistein co-treated with Carnitine] results in increased expression of CPT1A protein; Carnitine inhibits the reaction [quinone results in decreased expression of CPT1A protein]
Carnitine promotes the reaction [[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate]
Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB mRNA]; Carnitine inhibits the reaction [Sunitinib results in increased expression of CYBB protein]
Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of FABP9 protein]
Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK mRNA]; Carnitine inhibits the reaction [Gentamicins results in increased expression of HRK protein]
Carnitine inhibits the reaction [carbendazim results in decreased expression of IL10 protein]; Carnitine inhibits the reaction [Sunitinib results in decreased expression of IL10 mRNA]
Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of IL1B mRNA]]; Carnitine inhibits the reaction [sunitinib results in increased expression of IL1B mRNA]
Carnitine inhibits the reaction [carbendazim results in increased expression of IL6 protein]; Carnitine inhibits the reaction [Methotrexate results in increased expression of IL6 protein]; Carnitine inhibits the reaction [Sunitinib results in increased expression of IL6 mRNA]
INS1 protein results in decreased uptake of Carnitine Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased secretion of INS1 protein]
[Carboplatin co-treated with Carnitine deficiency] results in increased expression of MPO protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased activity of MPO protein]
Carnitine inhibits the reaction [carbendazim results in increased expression of NOS2 protein]; Carnitine inhibits the reaction [Ifosfamide results in increased expression of NOS2 mRNA]
[pirinixic acid results in increased activity of PPARA protein] promotes the reaction [SLC22A21 protein results in increased uptake of Carnitine]; PPARA protein promotes the reaction [Carnitine results in decreased susceptibility to Gentamicins] Carnitine results in increased activity of PPARA protein
Carnitine results in increased expression of PPARG protein Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of PPARG protein]
Carnitine results in increased expression of PTGIS mRNA PTGIS protein results in increased susceptibility to Carnitine [Carnitine results in increased expression of PTGIS mRNA] which results in increased chemical synthesis of 6-Ketoprostaglandin F1 alpha
[Doxorubicin co-treated with Carnitine] results in increased expression of SLC22A5 mRNA; Amiodarone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Atorvastatin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Betaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [SLC22A5 protein results in increased abundance of Doxorubicin]; Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; Choline inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Clozapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; grepafloxacin affects the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ipratropium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Lidocaine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Nifedipine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Olanzapine inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine analog]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Propranolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Quetiapine Fumarate inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Spironolactone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; talinolol inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; ziprasidone inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] Carnitine inhibits the reaction [SLC22A5 protein results in increased abundance of and results in increased localization of Doxorubicin] Carnitine results in decreased expression of SLC22A5 mRNA; Carnitine results in decreased expression of SLC22A5 protein 1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [Cyclophosphamide results in decreased expression of SLC22A5 protein]; Carnitine inhibits the reaction [Doxorubicin results in decreased expression of SLC22A5 mRNA]; Carnitine inhibits the reaction [SLC22A5 protein results in increased uptake of Tetraethylammonium]; Dithioerythritol inhibits the reaction [Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]]; Ofloxacin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine]; Omeprazole inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]; Tetraethylammonium inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] Carnitine deficiency results in increased expression of SLC22A5 mRNA SLC22A5 protein results in increased uptake of Carnitine; SLC22A5 protein results in increased uptake of Carnitine analog SLC22A5 protein affects the uptake of Carnitine Carnitine binds to SLC22A5 protein
Ampicillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Carnitine inhibits the reaction [Hydrogen Peroxide results in decreased activity of SLC25A20 protein]; Cefazolin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cefonicid inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Cephalothin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]; Piperacillin inhibits the reaction [SLC25A20 protein results in increased transport of Carnitine]
Carnitine results in increased expression of SLC2A4 protein Carnitine inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of SLC2A4 protein]
Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR mRNA]; Carnitine inhibits the reaction [carbendazim results in decreased expression of STAR protein]
Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TGFB1 mRNA]]; Carnitine inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of TGFB1 mRNA]; Carnitine inhibits the reaction [sunitinib results in increased expression of TGFB1 mRNA]
Carnitine deficiency results in increased expression of TNF mRNA [Carboplatin co-treated with Carnitine deficiency] results in increased expression of TNF protein; Acetaminophen promotes the reaction [Carnitine deficiency results in increased expression of TNF mRNA]; Carnitine inhibits the reaction [carbendazim results in increased expression of TNF protein]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF mRNA]]; Carnitine inhibits the reaction [Iohexol promotes the reaction [Glycerol results in increased expression of TNF protein]]; Carnitine inhibits the reaction [Methotrexate results in increased expression of TNF protein] Carnitine results in decreased expression of TNF protein
AG 1879 inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein]; resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of GJA1 protein]
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein resveratrol inhibits the reaction [1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased phosphorylation of MAPK1 protein]
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine binds to PTAFR protein 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of SELE mRNA 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of SELE protein
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased expression of TNF mRNA 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine results in increased secretion of TNF protein
[sodium arsenite co-treated with Platelet Activating Factor co-treated with Arachidonic Acid] results in increased phosphorylation of and results in increased activity of ALOX5 protein; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Calcimycin results in increased abundance of Platelet Activating Factor] Platelet Activating Factor results in increased expression of ALOX5 mRNA
Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]; EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]
EDNRB protein affects the reaction [Carbon Tetrachloride promotes the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]]; EDNRB protein affects the reaction [EDN1 protein results in increased abundance of Platelet Activating Factor]
[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein; IMMLG5521 inhibits the reaction [[Platelet Activating Factor co-treated with Cytochalasin B] results in increased secretion of GUSB protein]
Platelet Activating Factor results in increased expression of IL1B mRNA Platelet Activating Factor results in increased secretion of IL1B protein [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL1B protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein]
[Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of IL6 protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein]
Foropafant inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]; Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased expression of ITGAM protein]
Platelet Activating Factor results in increased expression of MYD88 protein PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein]
NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor]
Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Genistein inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; herbimycin inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased degradation of NFKBIA protein]
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50730 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; BN 50739 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; CMI 392 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; MK 287 inhibits the reaction [Platelet Activating Factor binds to PTAFR protein]; zileuton inhibits the reaction [Platelet Activating Factor binds to PTAFR protein] Platelet Activating Factor results in increased expression of PTAFR mRNA Platelet Activating Factor results in increased phosphorylation of PTAFR protein bepafant inhibits the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]; Carbon Tetrachloride promotes the reaction [Platelet Activating Factor binds to PTAFR protein]; RGS4 protein inhibits the reaction [Platelet Activating Factor results in increased phosphorylation of PTAFR protein]; TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA]
Platelet Activating Factor results in increased expression of PVT1 mRNA [Platelet Activating Factor co-treated with PVT1 mRNA] affects the expression of MIR149 mRNA; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased expression of MYD88 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL1B protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of IL6 protein]; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein]
Isoproterenol promotes the reaction [Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein]]; Theophylline inhibits the reaction [Platelet Activating Factor results in increased secretion of SELL protein]
Platelet Activating Factor results in increased secretion of TNF protein [Platelet Activating Factor co-treated with MIR149 mRNA] affects the secretion of TNF protein; PVT1 mRNA affects the reaction [Platelet Activating Factor results in increased secretion of TNF protein] TNF protein affects the reaction [Platelet Activating Factor results in increased expression of PTAFR mRNA] Platelet Activating Factor results in increased expression of TNF mRNA Acetylcysteine inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; BN 50739 inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]; Vitamin E inhibits the reaction [Platelet Activating Factor results in increased expression of TNF mRNA]
IDH2 protein mutant form results in increased abundance of 3-dehydrocarnitine Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 3-dehydrocarnitine]
4'-hydroxydiclofenac promotes the reaction [[Hydrogen Peroxide co-treated with MPO protein co-treated with Glutathione] results in increased glutathionylation of 5,5-dimethyl-1-pyrroline-1-oxide]; [[Hydrogen Peroxide results in increased activity of MPO protein] which results in increased oxidation of Glutathione] which results in increased glutathionylation of 5,5-dimethyl-1-pyrroline-1-oxide; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,4-dichloroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,4-xylidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,6-xylidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2-anisidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2-chloroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2-toluidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3,4-dichloroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3,4-xylidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3-anisidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3-chloroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3-toluidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-aminobenzonitrile] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-chloroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-ethylaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-fluoroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-nitroaniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-toluidine] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of Aminoglutethimide] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of aniline] which results in increased expression of MPO protein modified form; [[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of Procainamide] which results in increased expression of MPO protein modified form; [Hydrogen Peroxide co-treated with MPO protein co-treated with Glutathione] results in increased glutathionylation of 5,5-dimethyl-1-pyrroline-1-oxide; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,4-dichloroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,4-xylidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2,6-xylidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2-anisidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2-chloroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 2-toluidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3,4-dichloroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3,4-xylidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3-anisidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3-chloroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 3-toluidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-aminobenzonitrile; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-chloroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-ethylaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-fluoroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-nitroaniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of 4-toluidine; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of Aminoglutethimide; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of aniline; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of Procainamide; desmethylnaproxen promotes the reaction [[Hydrogen Peroxide co-treated with MPO protein co-treated with Glutathione] results in increased glutathionylation of 5,5-dimethyl-1-pyrroline-1-oxide]
pivaloylcarnitine binds to SLC22A5 protein SLC22A5 protein results in increased uptake of pivaloylcarnitine Carnitine inhibits the reaction [SLC22A5 protein results in increased transport of pivaloylcarnitine]; pivaloylcarnitine inhibits the reaction [SLC22A5 protein results in increased transport of Carnitine]
L-carnitine increases expression of Cpt1a mRNA and protein in rat heart L-carnitine inhibits the reaction [sunitinib decreases expression of Cpt1a mRNA and protein in rat heart]
L-carnitine increases expression of Mlycd protein in rat heart L-carnitine inhibits the reaction [sunitinib increases expression of Mlycd protein in rat heart]
L-carnitine increases expression of Ampka2 protein in rat serum and heart L-carnitine inhibits the reaction [sunitinib decreases expression of Ampka2 protein in rat serum and heart]
Ceftaroline inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Tobacco Smoke Pollution] results in decreased secretion of DEFB4A protein]; Ceftaroline inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of and results in decreased secretion of DEFB4A protein]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in decreased secretion of DEFB4A protein]
Ceftaroline inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution inhibits the reaction [IL1B protein results in increased expression of DEFB4A mRNA]]
Ceftaroline inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Tobacco Smoke Pollution] results in increased secretion of TNF protein]; Ceftaroline inhibits the reaction [Tobacco Smoke Pollution results in increased secretion of TNF protein]
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein]
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein]
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein]
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein]
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased expression of PIK3CA protein]
Ergothioneine inhibits the reaction [SLC22A4 protein results in increased abundance of and results in increased localization of Doxorubicin] Ergothioneine inhibits the reaction [SLC22A4 protein results in increased abundance of Doxorubicin]
Ergothioneine inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ABCC4 mRNA
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in increased expression of ACACA mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ACACB mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ADGRG2 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of AKR1B7 mRNA
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of ALDH2 protein
Betaine inhibits the reaction [Azacitidine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [Azacitidine results in increased expression of and results in increased cleavage of APP protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in increased expression of and results in increased cleavage of APP protein]
ATP7B protein mutant form promotes the reaction [Betaine results in increased abundance of S-Adenosylmethionine]; Betaine inhibits the reaction [ATP7B protein mutant form results in increased abundance of Copper]; Betaine inhibits the reaction [ATP7B protein mutant form results in increased expression of TNF mRNA]
Betaine inhibits the reaction [Ethanol results in increased expression of BRF1 mRNA]; Betaine inhibits the reaction [Ethanol results in increased expression of BRF1 protein]
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased activity of CAT protein Betaine inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein]; Betaine inhibits the reaction [Carbon Tetrachloride results in increased activity of CAT protein]
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in decreased expression of CCL2 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CDK1 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CES2C mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CLCF1 mRNA
Betaine inhibits the reaction [CPT1A protein mutant form results in decreased expression of DNMT1 mRNA] Betaine results in decreased expression of CPT1A mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP26A1 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2B10 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of CYP2C55 mRNA
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate] inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein] Betaine promotes the reaction [Ethanol results in increased expression of CYP2E1]
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of DEPP1 mRNA
Betaine inhibits the reaction [CPT1A protein mutant form results in decreased expression of DNMT1 mRNA] Betaine results in increased expression of DNMT1 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of E2F8 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of EGFR mRNA
Betaine results in increased expression of EGR1 mRNA [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of EGR1 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of ESCO2 mRNA
Betaine affects the localization of and results in increased secretion of F8 protein; Betaine affects the localization of and results in increased secretion of F8 protein mutant form Betaine results in increased secretion of F8 protein; Betaine results in increased secretion of F8 protein mutant form
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of FABP5 mRNA
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid] affects the reaction [[Dietary Fats co-treated with Dietary Sucrose] affects the methylation of FASN promoter]
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GADD45B mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of GADD45G mRNA
Betaine inhibits the reaction [Isoproterenol results in decreased activity of GAL protein]; Betaine inhibits the reaction [Isoproterenol results in increased activity of GAL protein]
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of GCK mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GNA14 mRNA
Betaine results in increased expression of GPCPD1 mRNA [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of GPCPD1 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GSTA5 mRNA; [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of GSTA5 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of GSTM3 mRNA
Betaine inhibits the reaction [Isoproterenol results in decreased activity of GUSB protein]; Betaine inhibits the reaction [Isoproterenol results in increased activity of GUSB protein]
IDH2 protein mutant form results in increased abundance of Betaine Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Betaine]
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of IRS2 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ITGA8 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ITGB4 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of KRT4 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of LEPR mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of LRATD1 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of LRRC24 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of MAP4K1 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MCM5 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MCM6 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MICAL1 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of MKI67 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of MYCL mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of NLRP12 mRNA
Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased expression of OGG1 protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of OGG1 promoter]
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of PER2 mRNA
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of PPARA protein Betaine results in decreased expression of PPARA mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of PPP1R3G mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of PRSS8 mRNA
Betaine inhibits the reaction [Azacitidine results in decreased methylation of PSEN1 promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of PSEN1 promoter]
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of RFX4 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of RGS16 mRNA
Betaine results in decreased expression of RRM2 mRNA [Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of RRM2 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of S100A8 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of SLC25A30 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of SOCS2 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc co-treated with Phenobarbital] results in increased expression of SULT1E1 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of ULK1 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in increased expression of USP2 mRNA
[Methionine co-treated with Choline co-treated with Folic Acid co-treated with Betaine co-treated with Vitamin B 12 co-treated with Zinc] results in decreased expression of VNN1 mRNA
stachydrine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein]; stachydrine inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of NFKBIA protein]; stachydrine inhibits the reaction [IL1B protein results in increased phosphorylation of RELA protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS4 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of ADAMTS5 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of IL6 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP13 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; stachydrine inhibits the reaction [IL1B protein results in increased secretion of TNF protein]
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]]; trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE protein] oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of ACE mRNA]]; trigonelline inhibits the reaction [Glucose results in increased expression of ACE mRNA]
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein] oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of ACE2 mRNA]]; trigonelline inhibits the reaction [Glucose results in decreased expression of ACE2 mRNA]
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]]; trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of AGT protein] oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of AGT mRNA]]; trigonelline inhibits the reaction [Glucose results in increased expression of AGT mRNA]
trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of ATG7 protein] ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]]; ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]]; trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of ATG7 protein]
trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of BAX protein] [trigonelline co-treated with Cisplatin] results in increased expression of BAX protein; [trigonelline co-treated with Etoposide] results in increased expression of BAX protein
trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in decreased expression of BCL2 protein] [trigonelline co-treated with Cisplatin] results in decreased expression of BCL2 protein; [trigonelline co-treated with Etoposide] results in decreased expression of BCL2 protein
trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of BECN1 protein] trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in decreased expression of BECN1 protein]; trigonelline inhibits the reaction [Palmitic Acid results in decreased expression of BECN1 protein]
trigonelline results in increased activity of CASP3 protein [trigonelline co-treated with Cisplatin] results in increased cleavage of CASP3 protein; [trigonelline co-treated with Etoposide] results in increased cleavage of CASP3 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased activity of CASP3 protein]
trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of CD36 protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of CD36 protein]
trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of NFE2L2 protein]
trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] trigonelline results in decreased phosphorylation of EGFR protein
oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]]; oltipraz inhibits the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]]; trigonelline affects the reaction [INS2 protein affects the expression of ACE mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE protein]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of ACE2 protein]; trigonelline affects the reaction [INS2 protein affects the expression of AGT mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of AGT protein]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]; trigonelline inhibits the reaction [INS2 protein affects the abundance of angiotensin I (1-7)]
trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein] trigonelline results in decreased phosphorylation of MAPK1 protein
trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] trigonelline results in decreased phosphorylation of MAPK3 protein
oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in decreased expression of MAS1 mRNA]]; trigonelline inhibits the reaction [Glucose results in decreased expression of MAS1 mRNA] oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]]; oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of MAS1 protein]
trigonelline inhibits the reaction [EGF protein results in increased phosphorylation of NFE2L2 protein]; trigonelline inhibits the reaction [ferric citrate affects the localization of NFE2L2 protein]; trigonelline inhibits the reaction [NFE2L2 protein results in decreased susceptibility to Cisplatin]; trigonelline inhibits the reaction [NFE2L2 protein results in decreased susceptibility to Etoposide]; trigonelline inhibits the reaction [Pyocyanine results in increased expression of and affects the localization of NFE2L2 protein] oltipraz affects the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein]]; oltipraz inhibits the reaction [trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 mRNA]; trigonelline affects the reaction [INS2 protein affects the expression of NFE2L2 protein] oltipraz inhibits the reaction [trigonelline inhibits the reaction [Glucose results in increased expression of NFE2L2 protein]]; trigonelline inhibits the reaction [Glucose results in increased expression of NFE2L2 protein] trigonelline results in decreased phosphorylation of NFE2L2 protein
trigonelline inhibits the reaction [ferric citrate results in increased expression of NQO1 protein]; trigonelline inhibits the reaction [Pyocyanine results in increased expression of NQO1 mRNA] trigonelline results in decreased expression of NQO1 mRNA; trigonelline results in decreased expression of NQO1 protein
trigonelline inhibits the reaction [Palmitic Acid results in increased cleavage of PARP1 protein] [trigonelline co-treated with Cisplatin] results in increased cleavage of PARP1 protein; [trigonelline co-treated with Etoposide] results in increased cleavage of PARP1 protein
ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein] trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of PPARG protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of PPARG protein]
trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of SQSTM1 protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SQSTM1 protein]
trigonelline inhibits the reaction [[Cholesterol, Dietary co-treated with Dietary Fats] results in increased expression of SREBF1 protein]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein] ATG7 protein affects the reaction [trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]]; trigonelline inhibits the reaction [Palmitic Acid results in increased expression of SREBF1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TNF protein]]; trigonelline inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of TNF protein]
Acetylcarnitine inhibits the reaction [Dexamethasone results in decreased activity of ACHE protein]; Acetylcarnitine inhibits the reaction [Dexamethasone results in increased activity of ACHE protein]
Acetylcarnitine inhibits the reaction [sodium arsenite results in increased activity of CASP3 protein]; Acetylcarnitine inhibits the reaction [Sodium Selenite results in increased expression of CASP3 mRNA]
Acetylcarnitine inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; Acetylcarnitine inhibits the reaction [Sodium Selenite results in decreased expression of CAT mRNA]
IDH2 protein mutant form results in increased abundance of Acetylcarnitine Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Acetylcarnitine]
Acetylcarnitine results in increased expression of PPARGC1A protein [Acetylcarnitine co-treated with Thioctic Acid] results in increased expression of PPARGC1A protein
[Acetylcarnitine co-treated with Thioctic Acid] inhibits the reaction [Rotenone results in increased expression of SNCA protein]; Acetylcarnitine inhibits the reaction [Rotenone results in increased expression of SNCA protein]
[perifosine co-treated with Butyrates] results in increased secretion of AIFM1 protein; [perifosine co-treated with trichostatin A] results in increased secretion of AIFM1 protein; [perifosine co-treated with vorinostat] results in increased secretion of AIFM1 protein
[perifosine co-treated with Butyrates] results in decreased activity of AKT1 protein; [perifosine co-treated with trichostatin A] results in decreased activity of AKT1 protein; [perifosine co-treated with Vorinostat] results in decreased activity of AKT1 protein; AKT1 protein modified form results in decreased activity of [perifosine co-treated with Butyrates]; AKT1 protein modified form results in decreased activity of [perifosine co-treated with trichostatin A]; AKT1 protein modified form results in decreased activity of [perifosine co-treated with Vorinostat]; perifosine inhibits the reaction [cyadox results in increased phosphorylation of AKT1 protein] perifosine results in decreased phosphorylation of AKT1 protein [perifosine co-treated with temsirolimus] results in decreased activity of AKT1 protein
[perifosine co-treated with Butyrates] results in decreased expression of BAK1 protein; [perifosine co-treated with trichostatin A] results in decreased expression of BAK1 protein; [perifosine co-treated with vorinostat] results in decreased expression of BAK1 protein
[perifosine co-treated with Butyrates] results in increased activity of BAX protein; [perifosine co-treated with trichostatin A] results in increased activity of BAX protein; [perifosine co-treated with vorinostat] results in increased activity of BAX protein
[perifosine co-treated with Butyrates] results in increased activity of CASP3 protein; [perifosine co-treated with trichostatin A] results in increased activity of CASP3 protein; [perifosine co-treated with vorinostat] results in increased activity of CASP3 protein perifosine results in decreased expression of CASP3 protein
[perifosine co-treated with Butyrates] results in increased activity of CASP8 protein; [perifosine co-treated with trichostatin A] results in increased activity of CASP8 protein; [perifosine co-treated with Vorinostat] results in increased activity of CASP8 protein; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [perifosine results in increased expression of CASP8 protein modified form]; LAT2 protein inhibits the reaction [perifosine results in increased expression of CASP8 protein modified form]
[perifosine co-treated with Butyrates] affects the localization of CYCS protein; [perifosine co-treated with trichostatin A] affects the localization of CYCS protein; [perifosine co-treated with vorinostat] affects the localization of CYCS protein
perifosine inhibits the reaction [cyadox results in increased expression of EGF]; perifosine inhibits the reaction [Hydrogen Peroxide results in increased expression of EGF]
[perifosine co-treated with cyadox] results in increased expression of FOXO1 mRNA; [perifosine co-treated with Hydrogen Peroxide] results in increased expression of FOXO1 mRNA perifosine inhibits the reaction [cyanoginosin LR results in increased phosphorylation of FOXO1 protein]
ixazomib inhibits the reaction [perifosine results in decreased expression of LAT2 protein]; LAT2 protein inhibits the reaction [perifosine results in increased cleavage of PARP1 protein]; LAT2 protein inhibits the reaction [perifosine results in increased expression of CASP8 protein modified form] LAT2 protein results in decreased susceptibility to perifosine
MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with Butyrates]; MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with trichostatin A]; MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with vorinostat]
[perifosine co-treated with Butyrates] results in decreased activity of MAPK1 protein; [perifosine co-treated with trichostatin A] results in decreased activity of MAPK1 protein; [perifosine co-treated with vorinostat] results in decreased activity of MAPK1 protein
[perifosine co-treated with Butyrates] results in decreased activity of MAPK3 protein; [perifosine co-treated with trichostatin A] results in decreased activity of MAPK3 protein; [perifosine co-treated with vorinostat] results in decreased activity of MAPK3 protein
[perifosine co-treated with Butyrates] results in increased activity of MAPK8 protein; [perifosine co-treated with trichostatin A] results in increased activity of MAPK8 protein; [perifosine co-treated with vorinostat] results in increased activity of MAPK8 protein
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [perifosine results in increased cleavage of PARP1 protein]; LAT2 protein inhibits the reaction [perifosine results in increased cleavage of PARP1 protein]
perifosine inhibits the reaction [cyadox results in increased expression of TP53 mRNA]; perifosine inhibits the reaction [cyadox results in increased expression of TP53 protein]; perifosine inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 mRNA]
[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide; [[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines; Edetic Acid inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]; Penicillamine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]; Trientine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of Phosphatidylcholines] which results in increased chemical synthesis of phosphatidylcholine hydroperoxide]
[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of COL1A1 mRNA]
GPX4 mutant form promotes the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; GPX4 protein inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]
Phosphatidylcholines results in increased expression of IL1B mRNA Phosphatidylcholines results in increased expression of and results in increased secretion of IL1B protein
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of Phosphatidylcholines LIPC gene mutant form results in increased abundance of Phosphatidylcholines
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of Phosphatidylcholines LIPG gene mutant form results in increased abundance of Phosphatidylcholines
[LTF protein co-treated with Phosphatidylcholines co-treated with Phytosterols] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of MMP2 mRNA]
PAFAH1B1 protein promotes the reaction [Terbutaline results in increased secretion of Phosphatidylcholines]; PAFAH1B1 protein promotes the reaction [Tetradecanoylphorbol Acetate results in increased secretion of Phosphatidylcholines] PAFAH1B1 protein results in increased secretion of Phosphatidylcholines
[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]; Ozone inhibits the reaction [[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]; Ozone inhibits the reaction [SFTPA1 protein polymorphism inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]
[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA]
[silybin co-treated with Phosphatidylcholines co-treated with Vitamin E] inhibits the reaction [Dimethylnitrosamine results in increased expression of TIMP1 mRNA]
GPX4 mutant form promotes the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; GPX4 protein inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; NOX4 mutant form inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite]; PAFAH2 inhibits the reaction [TNF protein results in increased abundance of Phosphatidylcholines metabolite] Phosphatidylcholines results in increased expression of TNF mRNA [LTF protein co-treated with Phosphatidylcholines co-treated with Phytosterols] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Phosphatidylcholines results in increased expression of and results in increased secretion of TNF protein
Glutathione inhibits the reaction [Pyocyanine results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of AKT1 protein]
Pyocyanine results in increased expression of GCLC mRNA [Pyocyanine results in increased localization of NFE2L2 protein] which results in increased expression of GCLC mRNA; trigonelline inhibits the reaction [Pyocyanine results in increased expression of GCLC mRNA]
Glutathione inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK1 protein]
Pyocyanine results in increased phosphorylation of MAPK3 protein Glutathione inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK3 protein]
1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with RTKI cpd] inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; [Pyocyanine results in increased localization of NFE2L2 protein] which results in increased expression of GCLC mRNA; [Pyocyanine results in increased localization of NFE2L2 protein] which results in increased expression of NQO1 mRNA; Pyocyanine results in increased expression of and affects the localization of NFE2L2 protein; RTKI cpd inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; trigonelline inhibits the reaction [Pyocyanine results in increased expression of and affects the localization of NFE2L2 protein] Pyocyanine results in increased activity of NFE2L2 protein
Pyocyanine results in increased expression of NQO1 mRNA [Pyocyanine results in increased localization of NFE2L2 protein] which results in increased expression of NQO1 mRNA; trigonelline inhibits the reaction [Pyocyanine results in increased expression of NQO1 mRNA]
S-Adenosylmethionine inhibits the reaction [Dicarbethoxydihydrocollidine results in increased expression of AFP mRNA] S-Adenosylmethionine results in decreased expression of AFP mRNA
AHR protein results in decreased abundance of S-Adenosylmethionine PEMT protein promotes the reaction [AHR protein results in decreased abundance of S-Adenosylmethionine]
[S-Adenosylmethionine co-treated with Hemin] results in increased expression of ALAS2 mRNA; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of ALAS2 mRNA]
Cysteine promotes the reaction [AS3MT protein binds to S-Adenosylmethionine]; Glutathione promotes the reaction [AS3MT protein binds to S-Adenosylmethionine]; S-Adenosylmethionine promotes the reaction [AS3MT protein binds to and results in increased methylation of arsenite]; tris(2-carboxyethyl)phosphine promotes the reaction [AS3MT protein binds to S-Adenosylmethionine]
S-Adenosylmethionine inhibits the reaction [Ethanol results in increased activity of CASP3 protein] S-Adenosylmethionine results in decreased activity of CASP3 protein
S-Adenosylmethionine inhibits the reaction [sodium arsenite results in decreased expression of CCN1 protein]; S-Adenosylmethionine inhibits the reaction [sodium arsenite results in decreased stability of CCN1 mRNA]
S-Adenosylmethionine results in decreased expression of COL1A1 mRNA S-Adenosylmethionine inhibits the reaction [LEP protein results in increased expression of COL1A1 mRNA]
S-Adenosylmethionine inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A2 mRNA]; S-Adenosylmethionine inhibits the reaction [SP1 protein binds to COL1A2 promoter]; S-Adenosylmethionine inhibits the reaction [TGFB1 protein binds to COL1A2 promoter] S-Adenosylmethionine results in decreased expression of COL1A2 mRNA
S-Adenosylmethionine results in decreased activity of CYP2E1 protein S-Adenosylmethionine inhibits the reaction [CYP2E1 protein results in increased metabolism of 4-nitrophenol]; S-Adenosylmethionine inhibits the reaction [CYP2E1 protein results in increased metabolism of Dimethylnitrosamine]; S-Adenosylmethionine inhibits the reaction [CYP2E1 protein results in increased metabolism of Ethanol] S-Adenosylmethionine inhibits the reaction [Acetaminophen results in decreased expression of CYP2E1 protein]; S-Adenosylmethionine promotes the reaction [Carbon Tetrachloride results in decreased expression of and results in decreased activity of CYP2E1 protein]
S-Adenosylmethionine inhibits the reaction [arsenic trioxide inhibits the reaction [DNMT1 protein binds to ESR1 promoter]]; S-Adenosylmethionine inhibits the reaction [arsenic trioxide results in decreased expression of DNMT1 protein]
S-Adenosylmethionine inhibits the reaction [arsenic trioxide results in decreased expression of DNMT3A protein] S-Adenosylmethionine inhibits the reaction [Dicarbethoxydihydrocollidine results in increased expression of DNMT3A mRNA]
[S-Adenosylmethionine co-treated with Arsenic] affects the expression of EGR1 mRNA; [S-Adenosylmethionine inhibits the reaction [Arsenic results in decreased methylation of EGR1 promoter]] which results in decreased expression of EGR1 mRNA; S-Adenosylmethionine inhibits the reaction [Arsenic results in decreased methylation of EGR1 promoter]
S-Adenosylmethionine inhibits the reaction [[arsenic trioxide results in increased expression of ESR1 protein] which results in increased expression of GREB1 mRNA]; S-Adenosylmethionine inhibits the reaction [[arsenic trioxide results in increased expression of ESR1 protein] which results in increased expression of TFF1 mRNA]; S-Adenosylmethionine inhibits the reaction [arsenic trioxide inhibits the reaction [DNMT1 protein binds to ESR1 promoter]]; S-Adenosylmethionine inhibits the reaction [arsenic trioxide results in decreased methylation of ESR1 promoter]; S-Adenosylmethionine inhibits the reaction [arsenic trioxide results in increased expression of ESR1 mRNA]; S-Adenosylmethionine inhibits the reaction [arsenic trioxide results in increased expression of ESR1 protein]
S-Adenosylmethionine inhibits the reaction [Lithocholic Acid affects the expression of GCLC mRNA]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid affects the expression of GCLC mRNA]]
S-Adenosylmethionine inhibits the reaction [[arsenic trioxide results in increased expression of ESR1 protein] which results in increased expression of GREB1 mRNA]; S-Adenosylmethionine inhibits the reaction [arsenic trioxide results in increased expression of GREB1 mRNA]
S-Adenosylmethionine inhibits the reaction [Lithocholic Acid affects the expression of GSS mRNA]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid affects the expression of GSS mRNA]]
[Progesterone co-treated with S-Adenosylmethionine] results in increased methylation of HAND2 promoter; S-Adenosylmethionine inhibits the reaction [Progesterone results in increased expression of HAND2 mRNA]
[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HBB mRNA; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HBB mRNA]
[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HMBS mRNA; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HMBS mRNA]
S-Adenosylmethionine inhibits the reaction [Thioacetamide results in increased expression of IL1B protein] S-Adenosylmethionine inhibits the reaction [fumonisin B1 results in increased expression of IL1B mRNA]
S-Adenosylmethionine inhibits the reaction [Thioacetamide results in increased expression of IL6 protein] S-Adenosylmethionine inhibits the reaction [fumonisin B1 results in increased expression of IL6 mRNA]
S-Adenosylmethionine results in decreased expression of KLF6 mRNA S-Adenosylmethionine inhibits the reaction [Dicarbethoxydihydrocollidine results in increased expression of KLF6 mRNA]
S-Adenosylmethionine inhibits the reaction [LEP protein results in increased expression of COL1A1 mRNA]; S-Adenosylmethionine inhibits the reaction [Vitamin K 3 results in increased expression of LEP mRNA]
S-Adenosylmethionine inhibits the reaction [Lithocholic Acid results in increased expression of MAF protein]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in increased expression of MAF protein]]
S-Adenosylmethionine inhibits the reaction [Lithocholic Acid results in increased expression of MAFG protein]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in increased expression of MAFG protein]]
S-Adenosylmethionine inhibits the reaction [TGFB1 protein results in increased phosphorylation of MAPK1 protein] [1,2-linoleoylphosphatidylcholine co-treated with S-Adenosylmethionine] inhibits the reaction [Vitamin K 3 results in increased phosphorylation of MAPK1 protein]; S-Adenosylmethionine inhibits the reaction [TGFB1 protein promotes the reaction [SP1 protein binds to MAPK1 protein modified form]]
S-Adenosylmethionine inhibits the reaction [TGFB1 protein results in increased phosphorylation of MAPK3 protein] [1,2-linoleoylphosphatidylcholine co-treated with S-Adenosylmethionine] inhibits the reaction [Vitamin K 3 results in increased phosphorylation of MAPK3 protein]; S-Adenosylmethionine inhibits the reaction [TGFB1 protein promotes the reaction [SP1 protein binds to MAPK3 protein modified form]]
S-Adenosylmethionine binds to MTR protein [glutathionylcobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form; [Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form; Aluminum inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Arsenic inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Glutathione inhibits the reaction [Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]]; Glutathione inhibits the reaction [Thimerosal inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]]; Glutathione promotes the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Lead inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; mecobalamin inhibits the reaction [Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]]; Mercury inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Thimerosal inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]
[S-Adenosylmethionine co-treated with Arsenic] results in increased expression of NFE2L2 mRNA; S-Adenosylmethionine inhibits the reaction [Lithocholic Acid results in decreased expression of NFE2L2 protein]; S-Adenosylmethionine promotes the reaction [Ursodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in decreased expression of NFE2L2 protein]]
S-Adenosylmethionine inhibits the reaction [[Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased phosphorylation of NFKBIA protein]
S-Adenosylmethionine inhibits the reaction [Hydrogen Peroxide results in decreased expression of NLGN3 mRNA]; S-Adenosylmethionine inhibits the reaction [Hydrogen Peroxide results in increased methylation of NLGN3 promoter]; S-Adenosylmethionine inhibits the reaction [Particulate Matter results in decreased expression of NLGN3 mRNA]; S-Adenosylmethionine inhibits the reaction [Particulate Matter results in decreased expression of NLGN3 protein]; S-Adenosylmethionine inhibits the reaction [Particulate Matter results in increased methylation of NLGN3 promoter]
S-Adenosylmethionine inhibits the reaction [Hydrogen Peroxide results in decreased expression of NRXN1 mRNA]; S-Adenosylmethionine inhibits the reaction [Hydrogen Peroxide results in increased methylation of NRXN1 promoter]; S-Adenosylmethionine inhibits the reaction [Particulate Matter results in decreased expression of NRXN1 mRNA]; S-Adenosylmethionine inhibits the reaction [Particulate Matter results in decreased expression of NRXN1 protein]; S-Adenosylmethionine inhibits the reaction [Particulate Matter results in increased methylation of NRXN1 promoter]
[[S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; [S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP; S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]
[S-Adenosylmethionine co-treated with Arsenic] affects the expression of PTGS2 mRNA; [S-Adenosylmethionine inhibits the reaction [Arsenic results in decreased methylation of PTGS2 promoter]] which results in decreased expression of PTGS2 mRNA; S-Adenosylmethionine inhibits the reaction [Arsenic results in decreased methylation of PTGS2 promoter]
[S-Adenosylmethionine co-treated with Arsenic] affects the expression of SOCS3 mRNA; [S-Adenosylmethionine inhibits the reaction [Arsenic results in decreased methylation of SOCS3 promoter]] which results in decreased expression of SOCS3 mRNA; S-Adenosylmethionine inhibits the reaction [Arsenic results in decreased methylation of SOCS3 promoter]
S-Adenosylmethionine inhibits the reaction [TGFB1 protein promotes the reaction [SP1 protein binds to MAPK1 protein modified form]]; S-Adenosylmethionine inhibits the reaction [TGFB1 protein promotes the reaction [SP1 protein binds to MAPK3 protein modified form]] S-Adenosylmethionine inhibits the reaction [SP1 protein binds to COL1A2 promoter]
S-Adenosylmethionine inhibits the reaction [[arsenic trioxide results in increased expression of ESR1 protein] which results in increased expression of TFF1 mRNA]; S-Adenosylmethionine inhibits the reaction [arsenic trioxide results in increased expression of TFF1 mRNA]
S-Adenosylmethionine inhibits the reaction [TGFB1 protein promotes the reaction [SP1 protein binds to MAPK1 protein modified form]]; S-Adenosylmethionine inhibits the reaction [TGFB1 protein promotes the reaction [SP1 protein binds to MAPK3 protein modified form]] S-Adenosylmethionine inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein]; S-Adenosylmethionine inhibits the reaction [TGFB1 protein binds to COL1A2 promoter]; S-Adenosylmethionine inhibits the reaction [TGFB1 protein results in increased phosphorylation of MAPK1 protein]; S-Adenosylmethionine inhibits the reaction [TGFB1 protein results in increased phosphorylation of MAPK3 protein]
[[S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] S-Adenosylmethionine inhibits the reaction [Thioacetamide results in increased expression of TNF protein]
[S-Adenosylmethionine analog co-treated with TPMT protein] results in increased methylation of 4-methylbenzenethiol; [S-Adenosylmethionine analog co-treated with TPMT protein] results in increased methylation of 4-nitrobenzenthiol; [S-Adenosylmethionine co-treated with TPMT protein] results in increased methylation of 4-methylbenzenethiol; [S-Adenosylmethionine co-treated with TPMT protein] results in increased methylation of 4-nitrobenzenthiol; S-Adenosylmethionine analog inhibits the reaction [[S-Adenosylmethionine co-treated with TPMT protein] results in increased methylation of 4-nitrobenzenthiol]; S-Adenosylmethionine inhibits the reaction [[S-Adenosylmethionine analog co-treated with TPMT protein] results in increased methylation of 4-nitrobenzenthiol]
S-Adenosylmethionine inhibits the reaction [monobutyl phthalate results in increased expression of VIM mRNA]; S-Adenosylmethionine inhibits the reaction [monobutyl phthalate results in increased expression of VIM protein] S-Adenosylmethionine inhibits the reaction [sodium arsenite results in decreased expression of VIM protein]
serpentine (alkaloid) results in decreased activity of CYP2D6 protein serpentine (alkaloid) inhibits the reaction [CYP2D6 protein affects the metabolism of Dextromethorphan]
browse the term
